Helen E Heslop, MD, DSc (Hon)

Professor

(832) 824-4662

Email

hheslop@bcm.edu

Positions

Professor: Departments of Medicine and Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Houston, TX, US

Director - Center for Cell and Gene Therapy: Baylor College of Medicine
Houston, TX, US
Texas Children's Hospital Houston Methodist

Dan L Duncan Chair: Baylor College of Medicine

Leader, Cancer Cell & Gene Therapy: Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Addresses

TX Childs Feigin Ctr (Office): Room: TXFC-164006
Houston, TX, 77030
United States
Phone: (832) 824-4671
hheslop@bcm.edu

Houston Methodist Hospital (Clinic): 6565 Fannin St., Suite 800
Houston, TX, 77030
United States
Phone: (713) 394-6250

Houston Methodist Hospital (Hospital): 6565 Fannin St., Suite 800
Houston, TX, 77030
United States
Phone: (713) 394-6250

Education

M.D. from University Of Otago, New Zealand: 01/1990 - Otago, New Zealand

Advanced Training from Royal Free Hospital: 01/1986 - London, United Kingdom

Advanced Training from Christchurch Hospital: 01/1982 - Christchurch, New Zealand

M.B.,Ch.B. from University Of Otago, New Zealand: 01/1980 - Otago, New Zealand

Certifications

Fellow of the Royal Australasian College of Physicians (FRACP)

Fellow of the Royal College of Pathologists of Australasia (FRCPA)

Honors & Awards

President: Foundation for Accreditation Cell Therapy (01/2012 - 12/2015)

President: American Society of Blood and Marrow Transplantation (02/2008 - 02/2009)

President: American Society of Gene and Cell Therapy (05/2017 - 05/2018)

Member: NCI Subcomittee A (08/2014 - 08/2020)

Chair: BMT-CTN Steering Committee (01/2020 - 01/2022)

Elected: Association of American Physicians (03/2004)

Elected: National Academy of Medicine (10/2021)

Professional Interests

Cell and Gene Therapy

Professional Statement

Helen Heslop is a physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. A key step in this strategy has been the translation of laboratory findings to Phase I and II clinical trials, as exemplified by studies of Epstein Barr virus-induced lymphoproliferative disease (EBV-LPD), a fatal complication in about 15% of recipients of unrelated or mismatched family member bone marrow transplants in the early 1990s. In collaboration with Dr Cliona Rooney, she developed methods for early diagnosis of this disease and procedures for generating cytotoxic T lymphocytes (CTLs) from bone marrow donors. These studies were the first to demonstrate that antigen-specific cytotoxic T cells could eradicate an established malignancy and because the cells were genetically marked, we obtained definitive evidence of cell expansion, trafficking to tumor sites and decade-long persistence. Subsequent protocols have extended this approach to Hodgkin's Disease, NHL and nasopharyngeal cancer. She has an additional focus in reconstituting antiviral immunity post transplant in collaboration with Drs. Rooney, Leen and Bollard and is currently leading an NHLBI-funded multicenter trial of allogeneic multivirus specific T cells. She therefore has extensive experience in developing and conducting transplant studies and cell and gene therapy studies under IND and has also obtained orphan drug designation for my initial study. Other areas of research focus in collaboration include identification of novel tumor antigens and genetic modification of CTLs to overcome tumor evasion strategies. In collaboration with Drs. Brenner, Dotti, Savoldo, Gottschalk and Ahded group they are also evaluating if transduction of CTLs with chimeric antigen receptors can allow targeting of CD19+ve, CD30+ve and her2neu+ve malignancies.

Websites

VIICTR Publications List

Selected Publications

Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. " Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. " Blood. 2007 Oct 15; 110 (8) : 2838-45.
Pubmed PMID: 17609424.
Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. " Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. " Blood. 2010 Feb 4; 115 (5) : 925-35.
Pubmed PMID: 19880495.
Bollard CM, Rooney CM, Heslop HE. " T-cell therapy in the treatment of post-transplant lymphoproliferative disease. " Nat Rev Clin Oncol. 2012 Aug 14; 9 (9) : 510-9.
Pubmed PMID: 22801669.
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. " Inducible apoptosis as a safety switch for adoptive cell therapy. " N. Engl. J. Med.. 2011 Nov 3; 365 (18) : 1673-83.
Pubmed PMID: 22047558.
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. " Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. " Blood. 2011 Dec 1; 118 (23) : 6050-6.
Pubmed PMID: 21984804.
Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. " Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. " Nat. Med.. 2008 Nov ; 14 (11) : 1264-70.
Pubmed PMID: 18978797.
Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. " A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. " Mol. Ther.. 2005 Nov ; 12 (5) : 933-41.
Pubmed PMID: 15979412.
Heslop HE. " A less sour sweet; blocking galectin. " Blood. 2011 Apr 21; 117 (16) : 4165-6.
Pubmed PMID: 21511962.
Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Joachim Deeg H, Blazar BR. " A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. " Blood. 2007 Mar 15; 109 (6) : 2657-62.
Pubmed PMID: 17110457.
Heslop HE. " A method for preparing leucocyte depleted erythrocytes from rat blood. " J. Immunol. Methods. 1978 ; 22 (41337) : 389-91.
Pubmed PMID: 355557.
Gottlieb DJ, Brenner MK, Heslop HE, Bianchi AC, Bello-Fernandez C, Mehta AB, Newland AC, Galazka AR, Scott EM, Hoffbrand AV. " A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. " Br. J. Cancer. 1989 Oct ; 60 (4) : 610-5.
Pubmed PMID: 2803933.
Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM. " A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. " Cancer Gene Ther.. 2004 Feb ; 11 (2) : 81-91.
Pubmed PMID: 14685154.
Lanyi A, Li B, Li S, Talmadge CB, Brichacek B, Davis JR, Kozel BA, Trask B, van den Engh G, Uzvolgyi E, Stanbridge EJ, Nelson DL, Chinault C, Heslop H, Gross TG, Seemayer TA, Klein G, Purtilo DT, Sumegi J. " A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus. " Genomics. 1997 Jan 1; 39 (1) : 55-65.
Pubmed PMID: 9027486.
Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM. " Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). " J. Immunother.. 2010 Apr ; 33 (3) : 305-15.
Pubmed PMID: 20445351.
Bollard CM, Rössig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM. " Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. " Blood. 2002 May 1; 99 (9) : 3179-87.
Pubmed PMID: 11964281.
Louis CU, Paulino AC, Gottschalk S, Bertuch AA, Chintagumpala M, Heslop HE, Russell HV. " A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. " J. Pediatr. Hematol. Oncol.. 2007 Jul ; 29 (7) : 500-5.
Pubmed PMID: 17609631.
Hale GA, Heslop HE, Krance RA, Brenner MA, Jayawardene D, Srivastava DK, Patrick CC. " Adenovirus infection after pediatric bone marrow transplantation. " Bone Marrow Transplant.. 1999 Feb ; 23 (3) : 277-82.
Pubmed PMID: 10084260.
Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E, Rooney CM. " Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. " Int. J. Cancer. 2001 Sep 1; 93 (5) : 706-13.
Pubmed PMID: 11477583.
Fletcher BD, Heslop HE, Kaste SC, Bodner S. " Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. " Pediatr Radiol. 1998 Jul ; 28 (7) : 492-6.
Pubmed PMID: 9662565.
Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. " Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. " Clin Transplant. ; 20 (3) : 389-93.
Pubmed PMID: 16824159.
Heslop HE, Brenner MK, Krance RA, Bowman L, Cunningham JM, Richardson S, Alexander B, Heideman R, Boyett JM, Srivastava DK, Marcus SG, Berenson R, Heimfeld S, Brown S. " Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. " Hum. Gene Ther.. 1996 Mar 20; 7 (5) : 655-67.
Pubmed PMID: 8845391.
Heslop HE, Hickton CM, Laird E, Tait JD, Doig JR, Beard EJ. " Twin pregnancy and parturition in a patient with the Bernard Soulier syndrome. " Scand J Haematol. 1986 Jul ; 37 (1) : 71-3.
Pubmed PMID: 3489980.
Heslop HE, Rooney CM, Rill DR, Krance RA, Brenner MK. " Use of gene marking in bone marrow transplantation. " Cancer Detect. Prev.. 1996 ; 20 (2) : 108-13.
Pubmed PMID: 8706035.
Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. " Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. " Lancet. 1995 Jan 7; 345 (8941) : 41530.
Pubmed PMID: 7799740.
Ahmed N, Heslop HE. " Viral lymphomagenesis. " Curr. Opin. Hematol.. 2006 Jul ; 13 (4) : 254-9.
Pubmed PMID: 16755222.
Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G. " Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. " Haematologica. 2013 Apr ; 98 (4) : 533-7.
Pubmed PMID: 23242592.
Heslop HE, Benaim E, Brenner MK, Krance RA, Stricklin LM, Rochester RJ, Billing R. " Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. " Lancet. 1995 Sep 23; 346 (8978) : 805-6.
Pubmed PMID: 7674747.
Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. " Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? " Mol. Ther.. 2012 Feb ; 20 (2) : 246-9.
Pubmed PMID: 22297819.
Heslop HE. " Safer CARS. " Mol. Ther.. 2010 Apr ; 18 (4) : 661-2.
Pubmed PMID: 20357776.
Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK. " Requirements for the adoptive transfer of antibody responses to a priming antigen in man. " J. Immunol.. 1990 Jan 15; 144 (2) : 541-7.
Pubmed PMID: 2136894.
Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. " Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. " Mol. Cancer. 2009 ; 8 : 106.
Pubmed PMID: 19922650.
Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. " Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. " Blood. 2003 Sep 15; 102 (6) : 2292-9.
Pubmed PMID: 12763937.
Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK. " Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. " Leukemia. 2010 Mar ; 24 (3) : 563-72.
Pubmed PMID: 20072155.
Heslop HE, Gottlieb DJ, Reittie JE, Bello-Fernandez C, Meager A, Prentice HG, Brenner MK. " Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. " Br. J. Haematol.. 1989 Jun ; 72 (2) : 122-6.
Pubmed PMID: 2503022.
Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA. " Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. " Biol. Blood Marrow Transplant.. 2008 Nov ; 14 (11) : 1298-304.
Pubmed PMID: 18940685.
Heslop HE, Fitzgerald PH, Beard ME. " Sustained complete remission in Richter's syndrome. " Cancer. 1987 Mar 1; 59 (5) : 1036-9.
Pubmed PMID: 3815263.
Smith FS, Rencher SD, Heslop HE, Hurwitz JL. " T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient. " Cancer Immunol. Immunother.. 1995 Aug ; 41 (2) : 104-10.
Pubmed PMID: 7656269.
Falkenburg JH, Heslop HE, Barrett AJ. " T cell therapy in allogeneic stem cell transplantation. " Biol. Blood Marrow Transplant.. 2008 Jan ; 14 (1) : 136-41.
Pubmed PMID: 18162234.
Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM. " T cell therapies. " Ernst Schering Found Symp Proc. 2006 ; (4) : 69-82.
Pubmed PMID: 17824182.
Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM. " Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). " Bone Marrow Transplant.. 2005 Dec ; 36 (11) : 1001-8.
Pubmed PMID: 16184180.
Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. " Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. " 2006 Jan ; 6 (4) : 342-7.
Pubmed PMID: 16507214.
Roskrow MA, Rooney CM, Heslop HE, Brenner MK, Krance RA, Gresik MV, McClain K, Aguilar LK, Grilley B, Rob E, Carrum G. " Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. " Hum. Gene Ther.. 1998 May 20; 9 (8) : 1237-50.
Pubmed PMID: 9625264.
Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. " Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. " Hum. Gene Ther.. 2000 Jul 1; 11 (10) : 1465-75.
Pubmed PMID: 10910143.
Heslop HE, Brenner MK, Rooney C, Krance RA, Roberts WM, Rochester R, Smith CA, Turner V, Sixbey J, Moen R. " Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. " Hum. Gene Ther.. 1994 Mar ; 5 (3) : 381-97.
Pubmed PMID: 8018749.
Heslop HE, Rooney CM. " Adoptive cellular immunotherapy for EBV lymphoproliferative disease. " Immunol. Rev.. 1997 Jun ; 157 : 217-22.
Pubmed PMID: 9255632.
Fujita Y, Rooney CM, Heslop HE. " Adoptive cellular immunotherapy for viral diseases. " Bone Marrow Transplant.. 2008 Jan ; 41 (2) : 193-8.
Pubmed PMID: 17982497.
Gottschalk S, Heslop HE, Rooney CM. " Adoptive immunotherapy for EBV-associated malignancies. " Leuk. Lymphoma. 2005 Jan ; 46 (1) : 41284.
Pubmed PMID: 15621775.
Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. " Adoptive immunotherapy for posttransplantation viral infections. " Biol. Blood Marrow Transplant.. 2004 Mar ; 10 (3) : 143-55.
Pubmed PMID: 14993880.
Smith CA, Ng CY, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM. " Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. " Leuk. Lymphoma. 1996 Oct ; 23 (41337) : 213-20.
Pubmed PMID: 9031101.
Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. " Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. " Curr. Top. Microbiol. Immunol.. 2001 ; 258 : 221-9.
Pubmed PMID: 11443864.
Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. " Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. " Blood. 2006 Sep 15; 108 (6) : 1797-808.
Pubmed PMID: 16741253.
Brenner MK, Heslop HE. " Adoptive T cell therapy of cancer. " Curr. Opin. Immunol.. 2010 Apr ; 22 (2) : 251-7.
Pubmed PMID: 20171074.
Bollard CM, Savoldo B, Rooney CM, Heslop HE. " Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. " Acta Haematol.. 2003 ; 110 (41308) : 139-48.
Pubmed PMID: 14583674.
Huls MH, Rooney CM, Heslop HE. " Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. " Acta Haematol.. 2003 ; 110 (41308) : 149-53.
Pubmed PMID: 14583675.
Tey SK, Bollard CM, Heslop HE. " Adoptive T-cell transfer in cancer immunotherapy. " Immunol. Cell Biol.. 2006 Jun ; 84 (3) : 281-9.
Pubmed PMID: 16681825.
Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. " Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. " J. Immunother.. ; 33 (9) : 983-90.
Pubmed PMID: 20948438.
Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. " Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. " Cytotherapy. 2010 Oct ; 12 (6) : 743-9.
Pubmed PMID: 20429793.
Shaffer DR, Sheehan AM, Yi Z, Rodgers CC, Bollard CM, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. " Aggressive peripheral CD70-positive t-cell lymphoma associated with severe chronic active EBV infection. " Pediatr Blood Cancer. 2012 Oct ; 59 (4) : 758-61.
Pubmed PMID: 21994111.
Hale GA, Tong X, Benaim E, Cunningham JM, Heslop HE, Horwiz EM, Leung W, Rochester RJ, Shearer PD, Srivastava DK, Woodard JP, Bowman LC. " Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. " Bone Marrow Transplant.. 2001 Jan ; 27 (2) : 155-62.
Pubmed PMID: 11281384.
Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Joachim Deeg H. " Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. " Br. J. Haematol.. 2011 Apr ; 153 (1) : 76-82.
Pubmed PMID: 21323890.
Heslop BF, Heslop HE. " Allogeneic red blood cells fail to induce haemagglutinating antibodies or cellular alloimmunity in rats and are immunosuppressive. " Transplantation. 1979 Aug ; 28 (2) : 144-8.
Pubmed PMID: 384621.
Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE. " Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. " Blood. 2010 Nov 25; 116 (22) : 4700-2.
Pubmed PMID: 20709906.
Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. " An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. " Blood. 2001 Feb 15; 97 (4) : 835-43.
Pubmed PMID: 11159505.
Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. " An inducible caspase 9 safety switch for T-cell therapy. " Blood. 2005 Jun 1; 105 (11) : 4247-54.
Pubmed PMID: 15728125.
Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G. " An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. " Stem Cells. 2010 Jun ; 28 (6) : 1107-15.
Pubmed PMID: 20506146.
Krance R, Heslop HE, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, Brenner MK. " Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. " Bone Marrow Transplant.. 1993 Jan ; 11 (1) : 33-6.
Pubmed PMID: 8431709.
Shafer JA, Cruz CR, Leen AM, Ku S, Lu A, Rousseau A, Heslop HE, Rooney CM, Bollard CM, Foster AE. " Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. " Leuk. Lymphoma. 2010 May ; 51 (5) : 870-80.
Pubmed PMID: 20367572.
Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. " Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. " J. Immunother.. 2008 Jun ; 31 (5) : 500-5.
Pubmed PMID: 18463534.
Jones RB, Anasetti C, Appel P, DiPersio J, Heslop H, Lemaistre F, Silver S, Sirilla J, Stiff P. " ASBMT committee report: white paper on measurement of quality outcomes. " Biol. Blood Marrow Transplant.. 2006 May ; 12 (5) : 594-7.
Pubmed PMID: 16635795.
Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. " Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. " J. Immunother.. ; 29 (3) : 250-60.
Pubmed PMID: 16699368.
Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. " Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. " Blood. 2002 Dec 1; 100 (12) : 4059-66.
Pubmed PMID: 12393655.
Brenner M, Krance R, Heslop HE, Santana V, Ihle J, Ribeiro R, Roberts WM, Mahmoud H, Boyett J, Moen RC. " Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. " Hum. Gene Ther.. 1994 Apr ; 5 (4) : 481-99.
Pubmed PMID: 8049305.
Heslop HE. " Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. " Hematology Am Soc Hematol Educ Program. 2005 ; 260-6.
Pubmed PMID: 16304390.
Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. " Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. " Biol. Blood Marrow Transplant.. 2007 Nov ; 13 (11) : 1268-85.
Pubmed PMID: 17950914.
Hale GA, Heslop HE, Bowman LC, Rochester RA, Pui CH, Brenner MK, Krance RA. " Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. " Bone Marrow Transplant.. 1999 Oct ; 24 (7) : 735-9.
Pubmed PMID: 10516676.
Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. " CARs on Track in the Clinic. " Mol. Ther.. 2011 Mar ; 19 (3) : 432-8.
Pubmed PMID: 21358705.
Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE. " CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. " Blood. 2000 Feb 15; 95 (4) : 1502-5.
Pubmed PMID: 10666232.
Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. " CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. " J. Clin. Invest.. 2011 May 2; 121 (5) : 1822-6.
Pubmed PMID: 21540550.
Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. " CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. " Bone Marrow Transplant.. 2005 Jun ; 35 (12) : 1127-32.
Pubmed PMID: 15834432.
Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA. " Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. " Am. J. Transplant.. 2005 Mar ; 5 (3) : 566-72.
Pubmed PMID: 15707412.
Heslop HE, Savoldo B, Rooney CM. " Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. " Best Pract Res Clin Haematol. 2004 Sep ; 17 (3) : 401-13.
Pubmed PMID: 15498712.
Mathew P, Bozeman P, Krance RA, Brenner MK, Heslop HE. " Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. " Bone Marrow Transplant.. 1994 Feb ; 13 (2) : 221-3.
Pubmed PMID: 8205095.
Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. " Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. " Brain. 2004 May ; 127 : 996-1008.
Pubmed PMID: 14985264.
Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. " Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. " Blood. 2011 Jun 2; 117 (22) : 5835-49.
Pubmed PMID: 21454450.
Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM. " Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. " J. Immunol.. 2005 Sep 15; 175 (6) : 4137-47.
Pubmed PMID: 16148164.
Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Heslop HE, Brenner MK, Krance RA. " Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. " Pediatr Blood Cancer. 2011 Jan ; 56 (1) : 143-51.
Pubmed PMID: 21108446.
Heslop HE. " Commentary on journal of immunotherapy paper by melenhorst et al. " J. Immunother.. ; 29 (4) : 365-6.
Pubmed PMID: 16799331.
Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA. " Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. " Biol. Blood Marrow Transplant.. 2008 Nov ; 14 (11) : 1245-52.
Pubmed PMID: 18940679.
Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA. " Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. " Biol. Blood Marrow Transplant.. 2006 Dec ; 12 (12) : 1277-84.
Pubmed PMID: 17162209.
Yotnda P, Zompeta C, Heslop HE, Andreeff M, Brenner MK, Marini F. " Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. " Hum. Gene Ther.. 2004 Dec ; 15 (12) : 1229-42.
Pubmed PMID: 15684699.
Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK. " Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. " Cytotherapy. 2011 Oct ; 13 (9) : 1128-39.
Pubmed PMID: 21745159.
Brenner MK, Wulf GG, Rill DR, Luo KL, Goodell MA, Mei Z, Kuehnle I, Brown MP, Pule M, Heslop HE, Krance RA. " Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. " Ann. N. Y. Acad. Sci.. 2003 May ; 996 : 80-8.
Pubmed PMID: 12799286.
Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. " Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. " Blood. 2007 Oct 15; 110 (8) : 2793-802.
Pubmed PMID: 17638856.
Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, Bollard CM, Wong ST. " Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. " Acad Radiol. 2010 Apr ; 17 (4) : 479-88.
Pubmed PMID: 20060747.
Rooney CM, Smith CA, Heslop HE. " Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. " Mol Med Today. 1997 Jan ; 3 (1) : 24-30.
Pubmed PMID: 9021739.
Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. " Correction of Duncan's syndrome by allogeneic bone marrow transplantation. " Lancet. 1993 Sep 4; 342 (8871) : 587-8.
Pubmed PMID: 8102723.
Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N. " Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment. " PLoS ONE. 2011 ; 6 (5) : e20267.
Pubmed PMID: 21647415.
Dotti G, Heslop HE. " Current status of genetic modification of T cells for cancer treatment. " Cytotherapy. 2005 ; 7 (3) : 262-72.
Pubmed PMID: 16081353.
Heslop HE. " Cytokine gene transfer in the therapy of malignancy. " Baillieres Clin. Haematol.. 1994 Mar ; 7 (1) : 135-51.
Pubmed PMID: 8038497.
Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. " Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. " Bone Marrow Transplant.. 2005 Nov ; 36 (9) : 797-802.
Pubmed PMID: 16151431.
Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. " Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. " J. Exp. Med.. 2004 Dec 20; 200 (12) : 1623-33.
Pubmed PMID: 15611290.
Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. " Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. " Blood. 2009 Nov 5; 114 (19) : 4283-92.
Pubmed PMID: 19700662.
Leen AM, Heslop HE. " Cytotoxic T lymphocytes as immune-therapy in haematological practice. " Br. J. Haematol.. 2008 Oct ; 143 (2) : 169-79.
Pubmed PMID: 18691164.
Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. " Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. " Blood. 2008 Sep 1; 112 (5) : 1876-85.
Pubmed PMID: 18591381.
Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. " Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. " Mol. Ther.. 2011 Dec ; 19 (12) : 2258-68.
Pubmed PMID: 21915103.
Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N. " Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. " Hum. Immunol.. 2011 Dec ; 72 (12) : 1214-6.
Pubmed PMID: 21723898.
Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N. " Definitions of histocompatibility typing terms. " Blood. 2011 Dec 1; 118 (23) : e180-3.
Pubmed PMID: 22001389.
Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. " Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. " Blood. 2010 Apr 1; 115 (13) : 2695-703.
Pubmed PMID: 20110422.
Wagner HJ, Rooney CM, Heslop HE. " Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. " Biol. Blood Marrow Transplant.. 2002 ; 8 (1) : 41282.
Pubmed PMID: 11846351.
Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. " Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. " Blood. 1994 Jul 15; 84 (2) : 380-3.
Pubmed PMID: 8025266.
Heslop HE, Brenner MK, Rooney CM. " Donor T cells to treat EBV-associated lymphoma. " N. Engl. J. Med.. 1994 Sep 8; 331 (10) : 679-80.
Pubmed PMID: 8052285.
Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. " Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. " Br. J. Haematol.. 1995 Jan ; 89 (1) : 98-103.
Pubmed PMID: 7833284.
Rooney CM, Heslop HE, Brenner MK. " EBV specific CTL: a model for immune therapy. " Vox Sang.. 1998 ; 74 : 497-8.
Pubmed PMID: 9704488.
Heslop HE, Bianchi AC, Cordingley FT, Turner M, Chandima W, De Mel CP, Hoffbrand AV, Brenner MK. " Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. " J. Exp. Med.. 1990 Dec 1; 172 (6) : 1729-34.
Pubmed PMID: 2258703.
Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK. " Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. " Blood. 1989 Nov 15; 74 (7) : 2335-42.
Pubmed PMID: 2804369.
Bianchi AC, Heslop HE, Drexler HG, Cordingley FT, Turner M, De Mel WC, Hoffbrand AV, Brenner MK. " Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. " Nouv Rev Fr Hematol. 1988 ; 30 (41400) : 317-9.
Pubmed PMID: 3265501.
Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, Davis A. " Efficient infection of primitive hematopoietic stem cells by modified adenovirus. " Gene Ther.. 2001 Jun ; 8 (12) : 930-7.
Pubmed PMID: 11426333.
Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK. " Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. " Blood. 1989 Apr ; 73 (5) : 1351-8.
Pubmed PMID: 2495037.
Ringwald-Smith KA, Heslop HE, Krance RA, Mackert PW, Hancock ML, Stricklin LM, Bowman LC, Hale GA. " Energy expenditure in children undergoing hematopoietic stem cell transplantation. " Bone Marrow Transplant.. 2002 Jul ; 30 (2) : 125-30.
Pubmed PMID: 12132052.
Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. " Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. " Leukemia. 2010 Jun ; 24 (6) : 1160-70.
Pubmed PMID: 20428207.
Bianchi AC, Heslop HE, Veys P, Macey M, Holland M, Prentice HG, Brenner MK. " Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. " Br. J. Haematol.. 1989 Dec ; 73 (4) : 468-74.
Pubmed PMID: 2692692.
Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. " Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. " Blood. 2009 Mar 12; 113 (11) : 2442-50.
Pubmed PMID: 18971421.
Pui CH, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH. " Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. " Leukemia. 1995 Dec ; 9 (12) : 1990-6.
Pubmed PMID: 8609707.
Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. " Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. " Blood. 2007 Oct 1; 110 (7) : 2620-30.
Pubmed PMID: 17507664.
Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. " Epstein-Barr infection after bone marrow transplantation. " Blood. 1994 Mar 15; 83 (6) : 1706-8.
Pubmed PMID: 8123864.
Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. " Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. " Recent Results Cancer Res.. 2002 ; 159 : 123-33.
Pubmed PMID: 11785836.
Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. " Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. " Blood. 1998 Apr 15; 91 (8) : 2925-34.
Pubmed PMID: 9531603.
Heslop HE. " Equal-opportunity treatment of EBV-PTLD. " Blood. 2012 Mar 15; 119 (11) : 2436-8.
Pubmed PMID: 22422813.
Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. " Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. " J. Exp. Med.. 2004 Feb 16; 199 (4) : 459-70.
Pubmed PMID: 14769850.
Ngo MC, Rooney CM, Howard JM, Heslop HE. " Ex vivo gene transfer for improved adoptive immunotherapy of cancer. " Hum. Mol. Genet.. 2011 Apr 15; 20 : R93-9.
Pubmed PMID: 21415041.
Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, Leung KS, Kennedy-Nasser A, Brenner MK, Heslop HE, Liu H, Wu MF, Hanson IC, Krance RA. " Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. " J. Allergy Clin. Immunol.. 2012 Jan ; 129 (1) : 176-83.
Pubmed PMID: 22078471.
Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. " Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. " Cytotherapy. 2011 Sep ; 13 (8) : 976-86.
Pubmed PMID: 21539497.
Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM. " Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. " J. Immunother.. 2008 Sep ; 31 (7) : 665-74.
Pubmed PMID: 18600178.
Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. " Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. " Blood. 2009 Aug 27; 114 (9) : 1958-67.
Pubmed PMID: 19443656.
Pule MA, Rousseau A, Vera J, Heslop HE, Brenner MK, Vanin EF. " Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. " Cytotherapy. 2008 ; 10 (5) : 526-39.
Pubmed PMID: 18821360.
Cela ME, Holladay MS, Rooney CM, Richardson S, Alexander B, Krance RA, Brenner MK, Heslop HE. " Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. " Bone Marrow Transplant.. 1996 Feb ; 17 (2) : 243-7.
Pubmed PMID: 8640174.
Duncombe AS, Meager A, Prentice HG, Grundy JE, Heslop HE, Hoffbrand AV, Brenner MK. " Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. " Blood. 1990 Sep 1; 76 (5) : 1046-53.
Pubmed PMID: 2168224.
Brenner MK, Heslop HE, Rooney CM. " Gene and cell transfer for specific immunotherapy. " Vox Sang.. 1998 ; 74 : 87-90.
Pubmed PMID: 9704428.
Brenner MK, Rill DR, Heslop HE, Rooney CM, Roberts WM, Li C, Nilson T, Krance RA. " Gene marking after bone marrow transplantation. " Eur. J. Cancer. 1994 ; 30 (8) : 1171-6.
Pubmed PMID: 7654451.
Wagner HJ, Sili U, Gahn B, Vigouroux S, Huls MH, Xie W, Vignali D, Brenner MK, Heslop HE, Rooney CM. " Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. " Cytotherapy. 2003 ; 5 (3) : 231-40.
Pubmed PMID: 12850791.
Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J, Anderson WF, Ihle JN. " Gene marking and autologous bone marrow transplantation. " Ann. N. Y. Acad. Sci.. 1994 May 31; 716 : 204-14; discuss.
Pubmed PMID: 8024195.
Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN. " Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. " Lancet. 1993 Nov 6; 342 (8880) : 1134-7.
Pubmed PMID: 7901474.
Rousseau RF, Bollard CM, Heslop HE. " Gene therapy for paediatric leukaemia. " Expert Opin Biol Ther. 2001 Jul ; 1 (4) : 663-74.
Pubmed PMID: 11727502.
Heslop HE. " Gene therapy of pediatric leukemia. " Clin. Lab. Med.. 2000 Mar ; 20 (1) : 183-95, x.
Pubmed PMID: 10702902.
Heslop HE. " Gene therapy. " Cytotherapy. 2007 ; 9 (6) : 519-20.
Pubmed PMID: 17882715.
Brenner MK, Heslop HE, Rill D, Li C, Nilson T, Roberts M, Smith C, Krance R, Rooney C. " Gene transfer and bone marrow transplantation. " Cold Spring Harb. Symp. Quant. Biol.. 1994 ; 59 : 691-7.
Pubmed PMID: 7587132.
Heslop HE, Roskrow M. " Gene transfer for the therapy of hematologic malignancy. " Curr. Opin. Hematol.. 1995 Nov ; 2 (6) : 417-22.
Pubmed PMID: 9372030.
Brenner MK, Cunningham JM, Sorrentino BP, Heslop HE. " Gene transfer into human hemopoietic progenitor cells. " Br. Med. Bull.. 1995 Jan ; 51 (1) : 167-91.
Pubmed PMID: 7767642.
Heslop HE, Rooney CM, Brenner MK. " Gene-marking and haemopoietic stem-cell transplantation. " Blood Rev.. 1995 Dec ; 9 (4) : 220-5.
Pubmed PMID: 8839397.
Bollard CM, Heslop HE, Brenner MK. " Gene-marking studies of hematopoietic cells. " Int. J. Hematol.. 2001 Jan ; 73 (1) : 14-22.
Pubmed PMID: 11372750.
Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM. " Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. " Blood. 2003 Mar 1; 101 (5) : 1905-12.
Pubmed PMID: 12411306.
Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM. " Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. " Transplantation. 2001 Sep 27; 72 (6) : 1078-86.
Pubmed PMID: 11579304.
Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM. " Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. " J. Immunol.. 2002 Jan 15; 168 (2) : 909-18.
Pubmed PMID: 11777989.
De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. " Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). " Blood. 2009 Nov 26; 114 (23) : 4784-91.
Pubmed PMID: 19759356.
Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N. " Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. " J. Immunother.. 2012 Feb ; 35 (2) : 159-68.
Pubmed PMID: 22306904.
Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. " Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. " Mol. Ther.. 2009 May ; 17 (5) : 880-8.
Pubmed PMID: 19259067.
Bonini C, Brenner MK, Heslop HE, Morgan RA. " Genetic modification of T cells. " Biol. Blood Marrow Transplant.. 2011 Jan ; 17 (1) : S15-20.
Pubmed PMID: 21195304.
Pule M, Bollard CM, Heslop HE. " Genetically engineered T-cells for adoptive immunotherapy. " Curr. Opin. Mol. Ther.. 2002 Oct ; 4 (5) : 467-75.
Pubmed PMID: 12435048.
Heslop H. " Getting personal with melanoma. " Clin. Cancer Res.. 2011 Jul 1; 17 (13) : 4189-91.
Pubmed PMID: 21712453.
Brenner MK, Heslop HE. " Graft versus leukaemia effects after marrow transplantation in man. " Baillieres Clin. Haematol.. 1991 Jul ; 4 (3) : 727-49.
Pubmed PMID: 1958889.
Brenner MK, Heslop HE. " Graft-versus-host reactions and bone-marrow transplantation. " Curr. Opin. Immunol.. 1991 Oct ; 3 (5) : 752-7.
Pubmed PMID: 1836732.
Rodriguez V, Kuehnle I, Heslop HE, Khan S, Krance RA. " Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation. " Bone Marrow Transplant.. 2002 Mar ; 29 (6) : 515-7.
Pubmed PMID: 11960272.
Horwitz EM, Horowitz MM, Difronzo NL, Kohn DB, Heslop HE. " Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. " Biol. Blood Marrow Transplant.. 2011 Feb ; 17 (2) : 192-6.
Pubmed PMID: 21182973.
Popat U, Carrum G, Heslop HE. " Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. " Cancer Treat. Rev.. 2003 Feb ; 29 (1) : 41343.
Pubmed PMID: 12633575.
Heslop HE. " Haemopoietic stem cell transplantation from unrelated donors. " Br. J. Haematol.. 1999 Apr ; 105 (1) : 41311.
Pubmed PMID: 10366243.
Krance RA, Kuehnle I, Rill DR, Mei Z, Pinetta C, Evans W, Brown MP, Pulé M, Heslop HE, Brenner MK. " Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. " Biol. Blood Marrow Transplant.. 2003 Apr ; 9 (4) : 273-81.
Pubmed PMID: 12720220.
Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. " Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. " Neurology. 2008 Oct 21; 71 (17) : 1326-34.
Pubmed PMID: 18936424.
Hale GA, Bowman LC, Rochester RJ, Benaim E, Heslop HE, Krance RA, Horwitz EM, Cunningham JM, Tong X, Srivastava DK, Handgretinger R, Jones DP. " Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. " Biol. Blood Marrow Transplant.. 2005 Nov ; 11 (11) : 912-20.
Pubmed PMID: 16275594.
Hale GA, Rochester RJ, Heslop HE, Krance RA, Gingrich JR, Benaim E, Horwitz EM, Cunningham JM, Tong X, Srivastava DK, Leung WH, Woodard P, Bowman LC, Handgretinger R. " Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. " Biol. Blood Marrow Transplant.. 2003 Nov ; 9 (11) : 698-705.
Pubmed PMID: 14652853.
Kauffman WM, Heslop HE, Gronemeyer SA, Chen G, Krance RA. " Hepatic arterial resistance index--an indicator of diffuse liver disease in children treated with bone marrow transplantation. " Clin Radiol. 1997 Dec ; 52 (12) : 903-6.
Pubmed PMID: 9413962.
Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. " HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. " Clin. Cancer Res.. 2010 Jan 15; 16 (2) : 474-85.
Pubmed PMID: 20068073.
Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. " High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. " Blood. 2011 Mar 24; 117 (12) : 3353-62.
Pubmed PMID: 21278353.
Bello-Fernandez C, Bird C, Heslop HE, Gottlieb DJ, Reittie JE, Rill DM, Holland M, Prentice HG, Brenner MK. " Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. " Blood. 1991 Mar 15; 77 (6) : 1283-9.
Pubmed PMID: 1900445.
Heslop HE. " How I treat EBV lymphoproliferation. " Blood. 2009 Nov 5; 114 (19) : 4002-8.
Pubmed PMID: 19724053.
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE,. " Human gene marker/therapy clinical protocols. " Hum. Gene Ther.. 1996 Aug 20; 7 (13) : 1621-47.
Pubmed PMID: 8864763.
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE,. " Human gene marker/therapy clinical protocols. " Hum. Gene Ther.. 1996 Dec 1; 7 (18) : 2287-313.
Pubmed PMID: 8953320.
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE,. " Human gene marker/therapy clinical protocols. " Hum. Gene Ther.. 1997 Dec 10; 8 (18) : 2301-38.
Pubmed PMID: 9449381.
Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. " Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. " Bone Marrow Transplant.. 2007 Jun ; 39 (11) : 705-9.
Pubmed PMID: 17401392.
Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM. " Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies. " J. Immunother.. 2013 Jan ; 36 (1) : 66-76.
Pubmed PMID: 23211628.
Heslop H, Richards AM, Nicholls MG, Espiner EA, Ikram H, Maslowski AH. " Hyponatraemic-hypertensive syndrome due to unilateral renal ischaemia in women who smoke heavily. " N. Z. Med. J.. 1985 Sep 11; 98 (786) : 739-42.
Pubmed PMID: 3863050.
Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. " Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. " J. Virol.. 2008 Jan ; 82 (1) : 546-54.
Pubmed PMID: 17942545.
Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, Wang RF. " Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. " Cancer Res.. 2002 Dec 15; 62 (24) : 7195-9.
Pubmed PMID: 12499257.
Gottlieb DJ, Prentice HG, Heslop HE, Bello C, Brenner MK. " IL-2 infusion abrogates humoral immune responses in humans. " Clin. Exp. Immunol.. 1992 Mar ; 87 (3) : 493-8.
Pubmed PMID: 1544235.
Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. " Immune therapy for EBV infections after hemopoietic stem-cell transplant. " Cytotherapy. 2002 ; 4 (5) : 433-4.
Pubmed PMID: 12473214.
Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. " Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. " Blood. 2013 Jan 3; 121 (1) : 207-18.
Pubmed PMID: 23152545.
Straathof KC, Bollard CM, Rooney CM, Heslop HE. " Immunotherapy for Epstein-Barr virus-associated cancers in children. " Oncologist. 2003 ; 8 (1) : 83-98.
Pubmed PMID: 12604735.
Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. " Immunotherapy for Epstein-Barr virus-associated cancers. " J. Natl. Cancer Inst. Monographs. 1998 ; (23) : 89-93.
Pubmed PMID: 9709309.
Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. " Immunotherapy for Hodgkin's disease. " Ann. Hematol.. 2002 ; 81 : S39-42.
Pubmed PMID: 12611071.
Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. " Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. " Mol. Ther.. 2009 Oct ; 17 (10) : 1779-87.
Pubmed PMID: 19532139.
Straathof KC, Savoldo B, Heslop HE, Rooney CM. " Immunotherapy for post-transplant lymphoproliferative disease. " Br. J. Haematol.. 2002 Sep ; 118 (3) : 728-40.
Pubmed PMID: 12181039.
Heslop HE, Stevenson FK, Molldrem JJ. " Immunotherapy of hematologic malignancy. " Hematology Am Soc Hematol Educ Program. 2003 ; 331-49.
Pubmed PMID: 14633789.
Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. " Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. " Blood. 2006 Feb 15; 107 (4) : 1332-41.
Pubmed PMID: 16249392.
Brenner MK, Heslop HE. " Immunotherapy of leukemia. " Leukemia. 1992 ; 6 : 76-9.
Pubmed PMID: 1548941.
Bollard CM, Cooper LJ, Heslop HE. " Immunotherapy targeting EBV-expressing lymphoproliferative diseases. " Best Pract Res Clin Haematol. 2008 Sep ; 21 (3) : 405-20.
Pubmed PMID: 18790446.
Gahn B, Hunt G, Rooney CM, Heslop HE. " Immunotherapy to reconstitute immunity to DNA viruses. " Semin. Hematol.. 2002 Jan ; 39 (1) : 41-7.
Pubmed PMID: 11799528.
Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. " Impending challenges in the hematopoietic stem cell transplantation physician workforce. " Biol. Blood Marrow Transplant.. 2009 Dec ; 15 (12) : 1493-501.
Pubmed PMID: 19781658.
Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. " Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. " Clin. Cancer Res.. 2011 Nov 15; 17 (22) : 7058-66.
Pubmed PMID: 21908573.
Heslop HE, Price GM, Prentice HG, Cordingley FT, Webster AD, Hoffbrand AV, Brenner MK. " In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. " J. Immunol.. 1988 May 15; 140 (10) : 3461-6.
Pubmed PMID: 3283234.
Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. " In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. " Leuk. Lymphoma. 2006 May ; 47 (5) : 837-42.
Pubmed PMID: 16753867.
Heslop HE, Gottlieb DJ, Bianchi AC, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. " In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. " Blood. 1989 Sep ; 74 (4) : 1374-80.
Pubmed PMID: 2504308.
Hutchings M, Moriwaki K, Dilloo D, Hoffmann T, Kimbrough S, Johnsen HE, Brenner MK, Heslop HE. " Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. " J Hematother. 1998 Jun ; 7 (3) : 217-24.
Pubmed PMID: 9621255.
Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. " Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. " Biol. Blood Marrow Transplant.. 2007 Aug ; 13 (8) : 913-24.
Pubmed PMID: 17640595.
Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. " Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. " Blood. 1998 Sep 1; 92 (5) : 1549-55.
Pubmed PMID: 9716582.
Sandlund JT, Bowman L, Heslop HE, Krance R, Mahmoud H, Pui CH, Hale G, Benaim E. " Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. " Cytotherapy. 2002 ; 4 (3) : 253-8.
Pubmed PMID: 12194721.
Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. " Interleukin 15 Provides Relief to CTLs from Regulatory T Cell-Mediated Inhibition: Implications for Adoptive T Cell-Based Therapies for Lymphoma. " Clin. Cancer Res.. 2013 Jan 1; 19 (1) : 106-17.
Pubmed PMID: 23149818.
Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. " Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. " Br. J. Haematol.. 1991 Feb ; 77 (2) : 237-44.
Pubmed PMID: 2004026.
Carter BA, Karpen SJ, Quiros-Tejeira RE, Chang IF, Clark BS, Demmler GJ, Heslop HE, Scott JD, Seu P, Goss JA. " Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. " Transplantation. 2002 Oct 15; 74 (7) : 1050-2.
Pubmed PMID: 12394854.
Brenner MK, Heslop HE. " Is retroviral gene marking too dangerous to use? " Cytotherapy. 2003 ; 5 (3) : 190-3.
Pubmed PMID: 12850996.
Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK. " Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. " Transplant. Proc.. 1991 Feb ; 23 (1) : 1704-5.
Pubmed PMID: 1989334.
Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. " Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. " J. Immunother.. ; 26 (3) : 241-56.
Pubmed PMID: 12806278.
Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. " Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. " Nat. Med.. 1996 May ; 2 (5) : 551-5.
Pubmed PMID: 8616714.
Katzav S, Cleveland JL, Heslop HE, Pulido D. " Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. " Mol. Cell. Biol.. 1991 Apr ; 11 (4) : 1912-20.
Pubmed PMID: 2005887.
Aguilar LK, Rooney CM, Heslop HE. " Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. " Curr Opin Oncol. 1999 Mar ; 11 (2) : 96-101.
Pubmed PMID: 10188073.
Gottlieb DJ, Prentice HG, Mehta AB, Galazka AR, Heslop HE, Hoffbrand AV, Brenner MK. " Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. " Br. J. Haematol.. 1990 Aug ; 75 (4) : 499-505.
Pubmed PMID: 2119792.
Comoli P, Dilloo D, Hutchings M, Hoffma T, Heslop HE. " Measuring gene-transfer efficiency. " Nat. Med.. 1996 Dec ; 2 (12) : 1280-1.
Pubmed PMID: 8946816.
Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. " Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. " Nat. Med.. 2006 Oct ; 12 (10) : 1160-6.
Pubmed PMID: 16998485.
Fernandez Vina M, Heslop HE, Barker JN. " New approaches in alternative donor transplantation. " Biol. Blood Marrow Transplant.. 2013 Jan ; 19 (1) : S91-6.
Pubmed PMID: 23110984.
Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM. " Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. " Mol. Ther.. 2009 Sep ; 17 (9) : 1616-25.
Pubmed PMID: 19584818.
Heslop HE, Gottschalk SM, Bollard CM, Straathof KC, Huls MH, Brenner MK, Rooney CM. " Options for T-cell based therapies. " Vox Sang.. 2004 Jul ; 87 : 230-4.
Pubmed PMID: 15209923.
Shafer JA, Heslop HE, Brenner MK, Carrum G, Wu MF, Liu H, Ahmed N, Gottschalk S, Kamble R, Leung KS, Myers GD, Bollard CM, Krance RA. " Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. " Leuk. Lymphoma. 2010 Apr ; 51 (4) : 664-70.
Pubmed PMID: 20367182.
Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. " Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). " Bone Marrow Transplant.. 2006 Mar ; 37 (6) : 547-52.
Pubmed PMID: 16462757.
Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM, Brenner MK, Heslop HE. " Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. " Lancet. 1997 Sep 13; 350 (9080) : 767-71.
Pubmed PMID: 9297996.
Cairo MS, Heslop H. " Pediatric blood and marrow transplantation: state of the science. " Bone Marrow Transplant.. 2008 Jan ; 41 (2) : 97.
Pubmed PMID: 18231112.
Heslop HE. " Pharmacotherapy versus T lymphocytes for CMV. " Blood. 2013 May 2; 121 (18) : 3544-5.
Pubmed PMID: 23640995.
Brenner MK, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J, Grilley B, Martingano E, Cooper K. " Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. " Hum. Gene Ther.. 2000 Jul 1; 11 (10) : 1477-88.
Pubmed PMID: 10910144.
Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O. " Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. " Transplantation. 2013 Feb 15; 95 (3) : 519-26.
Pubmed PMID: 23222884.
Kauffman WM, Zuckerman SL, Heslop HE, Krance RA. " Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade. " J Ultrasound Med. 1995 Nov ; 14 (11) : 877-9.
Pubmed PMID: 8551557.
Heslop HE, Brenner MK, Ganeshaguru K, Hoffbrand AV. " Possible mechanism of action of interferon alpha in chronic B-cell malignancies. " Br. J. Haematol.. 1991 Oct ; 79 : 14-6.
Pubmed PMID: 1931702.
Gottschalk S, Rooney CM, Heslop HE. " Post-transplant lymphoproliferative disorders. " Annu. Rev. Med.. 2005 ; 56 : 29-44.
Pubmed PMID: 15660500.
Kamdar KY, Rooney CM, Heslop HE. " Posttransplant lymphoproliferative disease following liver transplantation. " Curr Opin Organ Transplant. 2011 Jun ; 16 (3) : 274-80.
Pubmed PMID: 21467936.
Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, Prentice HG, Hazlehurst G, Hoffbrand AV. " Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. " Blood. 1991 May 1; 77 (9) : 1996-2001.
Pubmed PMID: 1708296.
Schriber JR, Anasetti C, Heslop HE, Leahigh AK. " Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. " Biol. Blood Marrow Transplant.. 2010 May ; 16 (5) : 595-7.
Pubmed PMID: 20167277.
Heslop HE. " Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation. " J. Immunother.. ; 24 (4) : 283-4.
Pubmed PMID: 11565828.
Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. " Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. " J Hematother. 1995 Apr ; 4 (2) : 73-9.
Pubmed PMID: 7633844.
Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM. " Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. " Cytotherapy. 2012 Jan ; 14 (1) : 41466.
Pubmed PMID: 22172091.
Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. " Prompt versus preemptive intervention for EBV lymphoproliferative disease. " Blood. 2004 May 15; 103 (10) : 3979-81.
Pubmed PMID: 14751931.
Phipps S, Brenner M, Heslop H, Krance R, Jayawardene D, Mulhern R. " Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. " Bone Marrow Transplant.. 1995 Jun ; 15 (6) : 829-35.
Pubmed PMID: 7581077.
Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, Gee AP, Scott JD, Savoldo B. " Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. " Clin Transplant. ; 20 (6) : 689-94.
Pubmed PMID: 17100717.
Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. " Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. " Am. J. Transplant.. 2005 Sep ; 5 (9) : 2222-8.
Pubmed PMID: 16095501.
Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. " Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections. " Mol. Ther.. 2012 Aug ; 20 (8) : 1622-32.
Pubmed PMID: 22801446.
Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE, Leen AM. " Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. " Bone Marrow Transplant.. 2007 Jun ; 39 (11) : 677-86.
Pubmed PMID: 17417664.
Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. " Regression of experimental medulloblastoma following transfer of HER2-specific T cells. " Cancer Res.. 2007 Jun 15; 67 (12) : 5957-64.
Pubmed PMID: 17575166.
Rencher SD, Hanif I, Heslop HE, Turner VE, Brenner MK, Hurwitz JL. " Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. " Bone Marrow Transplant.. 1992 Dec ; 10 (6) : 521-7.
Pubmed PMID: 1490202.
Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. " T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. " Blood. 2009 Jun 18; 113 (25) : 6392-402.
Pubmed PMID: 19377047.
Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G. " T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. " Blood. 2006 Dec 1; 108 (12) : 3890-7.
Pubmed PMID: 16926291.
Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM. " T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. " Ann. N. Y. Acad. Sci.. 2005 Dec ; 1062 : 104-15.
Pubmed PMID: 16461793.
Ahmed N, Heslop HE, Mackall CL. " T-cell-based therapies for malignancy and infection in childhood. " Pediatr. Clin. North Am.. 2010 Feb ; 57 (1) : 83-96.
Pubmed PMID: 20307713.
Heslop HE. " TCR expression; quantitative easing by CD3. " Blood. 2011 Sep 29; 118 (13) : 3452-3.
Pubmed PMID: 21960676.
Heslop HE, Brenner MK. " The clone ranger? " Mol. Ther.. 2008 Sep ; 16 (9) : 1520-1.
Pubmed PMID: 18725876.
Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA. " The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. " Biol. Blood Marrow Transplant.. 2010 Sep ; 16 (9) : 1272-81.
Pubmed PMID: 20348004.
Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. " The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. " J. Immunother.. ; 27 (4) : 317-27.
Pubmed PMID: 15235393.
Browett PJ, Heslop HE, Mehta AB, Norton JD. " The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage. " Acta Haematol.. 1990 ; 83 (4) : 203-5.
Pubmed PMID: 2142847.
Savoldo B, Heslop HE, Rooney CM. " The use of cytotoxic t cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients. " Leuk. Lymphoma. 2000 Nov ; 39 (41400) : 455-64.
Pubmed PMID: 11342329.
Heslop HE, Hoffbrand AV, Brenner MK. " TNF and chronic B lymphoproliferative disorders. " Leukemia. 1993 Sep ; 7 (9) : 1476.
Pubmed PMID: 8371597.
Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM. " Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. " J Clin Apher. 1999 ; 14 (3) : 154-6.
Pubmed PMID: 10540372.
Brenner MK, Heslop HE, Rill D, Li C, Smith C, Krance R, Rooney C. " Transfer of marker genes into hemopoietic progenitor cells. " Cytokines Mol Ther. 1996 Sep ; 2 (3) : 193-200.
Pubmed PMID: 9384704.
Ganguly S, Carrum G, Nizzi F, Heslop HE, Popat U. " Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. " Am. J. Hematol.. 2004 Jan ; 75 (1) : 48-51.
Pubmed PMID: 14695632.
Moriwaki K, Sutton RE, Perez M, Brenner MK, Heslop HE. " Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. " Cytotherapy. 1999 ; 1 (6) : 433-8.
Pubmed PMID: 20426543.
Kamble RT, Clark DA, Leong HN, Heslop HE, Brenner MK, Carrum G. " Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. " Bone Marrow Transplant.. 2007 Sep ; 40 (6) : 563-6.
Pubmed PMID: 17637686.
Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. " Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. " Transplantation. 2004 Sep 15; 78 (5) : 755-7.
Pubmed PMID: 15371682.
Gottschalk S, Heslop HE, Roon CM. " Treatment of Epstein-Barr virus-associated malignancies with specific T cells. " Adv. Cancer Res.. 2002 ; 84 : 175-201.
Pubmed PMID: 11883527.
Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. " Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. " Blood. 2005 Mar 1; 105 (5) : 1898-904.
Pubmed PMID: 15542583.
Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. " Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. " Ann. Oncol.. 1998 ; 9 : S129-32.
Pubmed PMID: 9926252.
Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. " Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). " Blood. 2006 Nov 1; 108 (9) : 2942-9.
Pubmed PMID: 16835376.
Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE. " Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. " Blood. 2001 Oct 1; 98 (7) : 2052-8.
Pubmed PMID: 11567989.
Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exley T, Brenner MK. " Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. " J. Immunol.. 1989 Dec 1; 143 (11) : 3828-34.
Pubmed PMID: 2584719.
Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. " Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. " Lancet. 1988 Apr 30; 1 (8592) : 969-71.
Pubmed PMID: 2896830.
Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. " XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. " Bone Marrow Transplant.. 1994 May ; 13 (5) : 571-5.
Pubmed PMID: 7519937.

Funding

SPORE in Lymphoma #P50 CA126752: $1,519,185.00 (09/01/2007 - 08/31/2027); Grant funding from NCI; The overall goal of the Lymphoma SPORE at Baylor College of Medicine and Houston Methodist Hospital is to devise in the laboratory, and validate in the clinic, interventional strategies, with the broad objective of improving outcome in lymphomas and in chronic lymphocytic leukemia (CLL).

Immunotherapy of Hematologic Malignancy: $1,250,000.00 (10/01/2018 - 09/30/2023); Grant funding from Leukemia and Lymphoma Society; The major goals of this program are to develop immunotherapy approaches for a broad range of hematologic malignancies

Training in Cell and Gene Therapy #T32 HL092332: $276,642.00 (07/01/2003 - 06/30/2028); Grant funding from NHLBI; This is a training grant for graduate students and postdoctoral fellows in Cell and Gene Therapy.

Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers (U01) #U10 HL10894: $100,000.00 (08/08/2011 - 06/30/2031); Grant funding from NHLBI

Meg Vosburg T cell Lymphoma Dream Team: $8,000,000.00 (03/01/2019 - 10/01/2023); Grant funding from AACR Stand Up To Cancer